Synlogic To Present at Upcoming Investor and Industry Conferences
On February 8, 2022, Synlogic, a clinical-stage biotechnology company (Nasdaq: SYBX), announced upcoming presentations at key investor conferences. Molly Harper, Chief Business Officer, will present at the BIO CEO & Investor Conference on February 14, 2022, while Aoife Brennan, CEO, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. The company focuses on developing medicines for metabolic diseases using Synthetic Biotics, with a pivotal Phase 3 study for phenylketonuria (PKU) planned for the second half of 2022.
- None.
- None.
CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that members of the executive team will present at the following investor and industry conferences:
- BIO CEO & Investor Conference: Molly Harper, Chief Business Officer, will present at 10:00 am EST on Monday, February 14, 2022.
- 11th Annual SVB Leerink Global Healthcare Conference: Aoife Brennan, M.B. Ch.B., President and Chief Executive Officer, will participate in a Fireside Chat at 12:00 pm EST on Thursday, February 17, 2022.
A live webcast of the presentations, if available, can be accessed under "Event Calendar" in the Investors & Media section of the Company's website. Archived versions of webcasts will be available on the Synlogic website.
About Synlogic
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic’s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic’s approach to Synthetic Biotics with Ginkgo’s Codebase and Foundry services. For additional information visit www.synlogictx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism, and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618, SYNB1934, SYNB1353 and SYNB8802 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
SOURCE Synlogic, Inc.
Media Contact:
Bill Berry
Berry & Company Public Relations
212-253-8881; bberry@berrypr.com
Investor Contact:
Andrew Funderburk
Kendall Investor Relations
617-914-0008; afunderburk@kendallir.com
FAQ
When will Synlogic present at the BIO CEO & Investor Conference?
Who from Synlogic will participate in the Fireside Chat at the SVB Leerink Conference?
What is Synlogic's lead program focus?
What is the stock symbol for Synlogic?
What is the significance of Synlogic's Synthetic Biotics?
